Clinical Trials Logo
  1. Home
  2. Pulmonary Hypertension
  3. NCT06365372
  4. Details
NCT06365372 Clinical Trial

Circulating MrgD in Pulmonary Hypertension

Pulmonary Hypertension Clinical Trial

Official title:
Circulating MrgD Change in Patients With Pulmonary Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06365372
Other study ID # MrgD and PAH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 10, 2024
Est. completion date June 1, 2024

Study information
Verified date April 2024
Source Qilu Hospital of Shandong University
Contact Panpan Hao, MD
Phone 8618560086593
Email panda.how@sdu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.

Recruitment information / eligibility
Status Recruiting
Enrollment 90
Est. completion date June 1, 2024
Est. primary completion date May 10, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for patients with pulmonary hypertension: 1. Male or female aged =18 years 2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) =25mmHg 3. The patient is willing and able to provide written informed consent. Exclusion criteria for patients with pulmonary hypertension: 1. Age less than 18 years old 2. Mean pulmonary artery pressure (mPAP) <25mmHg 3. Unable to provide informed written consent for participation in the study 4. Renal insufficiency 5. Liver insufficiency 6. Malignant tumor 7. Active infection 8. Pregnancy Inclusion criteria for control subjects: 1. Male or female aged =18 years 2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) < 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease 3. No evidence of clinically relevant pulmonary disease Exclusion criteria for control subjects: 1. Age less than 18 years old 2. Mean pulmonary artery pressure (mPAP) =25mmHg 3. Unable to provide informed written consent for participation in the study 4. Symptoms of heart failure or clinically relevant lung disease 5. Renal insufficiency 6. Liver insufficiency 7. Malignant tumor 8. Active infection 9. Pregnancy

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Western blot
Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.

Locations
Country Name City State
China Qilu Hospital of Shandong University Jinan Shandong

Sponsors (1)
Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Circulating MrgD level From 2022 to 2024
See also
  Status Clinical Trial Phase
Withdrawn NCT01950585 - Hydroxyurea in Pulmonary Arterial Hypertension Early Phase 1
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Recruiting NCT04554160 - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT01894035 - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting NCT04083729 - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy N/A
Completed NCT02821156 - Study on the Use of Inhaled NO (iNO) N/A
Completed NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Recruiting NCT01913847 - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT06240871 - Contrast Enhanced PA Pressure Measurements
Completed NCT02377934 - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting NCT01091012 - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Phase 3
Completed NCT00739375 - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension. Phase 1
Completed NCT01463514 - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Completed NCT01484899 - Smoking: a Risk Factor for Pulmonary Arterial Hypertension? N/A